Bonifant, C. L., Jackson, H. J., Brentjens, R. J., Curran, K. J. (2016). Toxicity and management in CAR T-cell therapy. Molecular Therapy Oncolytics, 3, 16011. https://doi.org/10.1038/mto.2016.11
Google Scholar | Crossref | Medline Brouwers, M. C., Kho, M. E., Browman, G. P., Burgers, J. S., Cluzeau, F., Feder, G., Fervers, B., Graham, I. D., Grimshaw, J., Hanna, S. E., Littlejohns, P., Makarski, J., Zitzelsberger, L., & AGREE Next Steps Consortium (2010). AGREE II: Advancing guideline development, reporting and evaluation in health care. CMAJ: Canadian Medical Association Journal, 182(18), E839–E842. https://doi.org/10.1503/cmaj.090449
Google Scholar | Crossref | Medline | ISI Brudno, J. N., Kochenderfer, J. N. (2016). Toxicities of chimeric antigen receptor T cells: Recognition and management. Blood, 127(26), 3321–3330. https://doi.org/10.1182/blood-2016-04-703751
Google Scholar | Crossref | Medline Davila, R., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S. S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., Qu, J., Wasielewska, T., He, Q., Fink, M., Shinglot, H., Youssif, M., Satter, M., Wang, Y., Hosey, J., Quintanilla, H., … Brentjens, R. (2014). Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Science Translational Medicine, 6(224), 224ra25. https://doi.org/10.1126/scitranslmed.3008226
Google Scholar Fitzgerald, J. C., Weiss, S. L., Maude, S. L., Barrett, D. M., Lacey, S. F., Melenhorst, J. J., Shaw, P., Berg, R. A., June, C. H., Porter, D. L., Frey, N. V., Grupp, S. A., Teachey, D. T. (2017). Cytokine release syndrome after chimeric antigen receptor t cell therapy for acute lymphoblastic leukemia. Critical Care Medicine, 45(2), e124–e131. https://doi.org/10.1097/ccm.0000000000002053
Google Scholar | Crossref | Medline Folan, S., Rexwinkle, A., Autry, J., Bryan, J. C. (2016). Blinatumomab: Bridging the gap in adult relapsed/refractory B-cell acute lymphoblastic leukemia. Clinical Lymphoma, Myeloma & Leukemia, 16(S1), S2–S5. https://doi.org/10.1016/j.clml.2016.02.001
Google Scholar | Crossref | Medline Frey, N. V., Porter, D. L. (2016). Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia. Hematology. American Society of Hematology Education Program, 2016(1), 567–572. https://doi.org/10.1182/asheducation-2016.1.567
Google Scholar | Crossref | Medline Genentech, Inc. (2017). ActemraⓇ (Tocilizumab): Highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125276s114lbl.pdf
Google Scholar Halton, E., Llerandi, D., Diamonte, C., Quintanilla, H., Miale-Mayer, D. (2017). Developing infrastructure: Managing patients with cancer undergoing car t-cell therapy. Clinical Journal of Oncology Nursing, 21(2 Suppl), 35–40. https://doi.org/10.1188/17.CJON.2.35-40
Google Scholar | Crossref | Medline Hu, Y., Wu, Z., Luo, Y., Shi, J., Yu, J., Pu, C., Liang, Z., Wei, G., Cui, Q., Sun, J., Jiang, J., Xie, J., Tan, Y., Ni, W., Tu, J., Wang, J., Jin, A., Zhang, H., Cai, Z., … Huang., H. (2017). Potent anti-leukemia activities of chimeric antigen receptor-modified t cells against CD19 in Chinese patients with relapsed/refractory acute lymphocytic leukemia. Clinical Cancer Research, 23(13), 3297–3306. https://doi.org/10.1158/1078-0432.ccr-16-1799
Google Scholar | Crossref | Medline Kelly, K. P., Hooke, M. C., Ruccione, K., Landier, W., Haase, J. (2014). Developing an organizing framework to guide nursing research in the children’s oncology group (COG). Seminars in Oncology Nursing, 30(1), 17–35. https://doi.org/10.1016/j.soncn.2013.12.004
Google Scholar | Crossref | Medline Landier, W., Leonard, M., Ruccione, K. S. (2013). Children’s oncology group’s 2013 blueprint for research: Nursing discipline. Pediatric Blood & Cancer, 60(6), 1031–1036. https://doi.org/10.1002/pbc.24415
Google Scholar | Crossref | Medline | ISI Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., Mackall, C. L. (2014). Current concepts in the diagnosis and management of cytokine release syndrome. Blood, 124(2), 188–195. https://doi.org/10.1182/blood-2014-05-552729
Google Scholar | Crossref | Medline | ISI Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., Steinberg, S. M., Stroncek, D., Tschernia, N., Yuan, C., Zhang, H., Zhang, L., Rosenberg, S. A., Wayne, A. S., Mackall, C. L. (2015). T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial. Lancet, 385(9967), 517–528. https://doi.org/10.1016/s0140-6736(14)61403-3
Google Scholar | Crossref | Medline Maude, S. L., Barrett, D., Teachey, D. T., Grupp, S. A. (2014a). Managing cytokine release syndrome associated with novel T cell-engaging therapies. The Cancer Journal, 20(2), 119–122. https://doi.org/10.1097/PPO.0000000000000035
Google Scholar | Crossref | Medline Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., Mahnke, Y. D., Melenhorst, J. J., Rheingold, S. R., Shen, A., Teachey, D. T., Levine, B. L., June, C. H., Porter, D. L., Grupp, S. A. (2014b). Chimeric antigen receptor T cells for sustained remissions in leukemia. New England Journal of Medicine, 371(16), 1507–1517. https://doi.org/10.1056/NEJMoa1407222
Google Scholar | Crossref | Medline Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., Qayed, M., De Moerloose, B., Hiramatsu, H., Schlis, K., Davis, K. L., Martin, P. L., Nemecek, E. R., Yanik, G. A., Peters, C., … Grupp, S. A. (2018). Tisagenlecleucel in children and young adults with b-cell lymphoblastic leukemia. New England Journal of Medicine, 378(5), 439–448. https://doi.org/10.1056/NEJMoa1709866
Google Scholar | Crossref | Medline Melnyk, B. M., Fineout-Overholt, E., Stillwell, S. B., Williamson, K. M. (2010). Evidence-based practice: Step by step: The seven steps of evidence-based practice. The American Journal of Nursing, 110(1), 51–53. https://doi.org/10.1097/01.NAJ.0000366056.06605.d2
Google Scholar | Crossref | Medline | ISI Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & PRISMA Group . (2009). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Medicine, 6(7), e1000097. https://doi.org/10.1371/journal.pmed.1000097
Google Scholar | Crossref | Medline | ISI National Cancer Institute. (2010). Common terminology criteria for adverse events v4.03. National Institutes of Health. https://ctep.cancer.gov/protocolDevelopment/adverse_effects.htm
Google Scholar Neelapu, S. S., Tummala, S., Kebriaei, P., Wierda, W., Gutierrez, C., Locke, F. L., Komanduri, K. V., Lin, Y., Jain, N., Daver, N., Westin, J., Gulbis, A. M., Loghin, M. E., de Groot, J. F., Adkins, S., Davis, S. E., Rezvani, K., Hwu, P., Shpall, E. J. (2018). Chimeric antigen receptor T-cell therapy—assessment and management of toxicities. Nature Reviews: Clinical Oncology, 15(1), 47–62. https://doi.org/10.1038/nrclinonc.2017.148
Google Scholar | Crossref | Medline Neumann, I., Santesso, N., Akl, E. A., Rind, D. M., Vandvik, P. O., Alonso-Coello, P., Agoritsas, T., Mustafa, R. A., Alexander, P. E., Schünemann, H., Guyatt, G. H. (2016). A guide for health professionals to interpret and use recommendations in guidelines developed with the GRADE approach. Journal of Clinical Epidemiology, 72, 45–55. https://doi.org/10.1016/j.jclinepi.2015.11.017
Google Scholar | Crossref | Medline Porter, D. L., Hwang, W. T., Frey, N. V., Lacey, S. F., Shaw, P. A., Loren, A. W., Bagg, A., Marcucci, K. T., Shen, A., Gonzalez, V., Ambrose, D., Grupp, S. A., Chew, A., Zheng, Z., Milone, M. C., Levine, B. L., Melenhorst, J. J., June, C. H. (2015). Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Science Translational Medicine, 7(303), 303ra139. https://doi.org/10.1126/scitranslmed.aac5415
Google Scholar | Crossref | Medline Pui, C. H., Yang, J. J., Hunger, S. P., Pieters, R., Schrappe, M., Biondi, A., Vora, A., Baruchel, A., Silverman, L. B., Schmiegelow, K., Escherich, G., Horibe, K., Benoit, Y. C., Izraeli, S., Yeoh, A. E., Liang, D. C., Downing, J. R., Evans, W. E., Relling, M. V., Mullighan, C. G. (2015). Childhood acute lymphoblastic leukemia: Progress through collaboration. Journal of Clinical Oncology, 33(27), 2938–2948. https://doi.org/10.1200/JCO.2014.59.1636
Google Scholar | Crossref | Medline | ISI Smith, L., Venella, K. (2017). Cytokine release syndrome: Inpatient care for Side effects of CAR T-cell therapy. Clinical Journal of Oncology Nursing, 21(2 Suppl), 29–34. https://doi.org/10.1188/17.CJON.S2.29-34
Google Scholar | Crossref | Medline Stein, A., Franklin, J. L., Chia, V. M., Arrindell, D., Kormany, W., Wright, J., Parson, M., Amouzadeh, H. R., Choudhry, J., Joseph, G. (2019). Benefit–risk assessment of blinatumomab in the treatment of relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Drug Safety, 42(5), 587–601. https://doi.org/10.1007/s40264-018-0760-1
Google Scholar | Crossref | Medline Sun, W., Malvar, J., Sposto, R., Verma, A., Wilkes, J. J., Dennis, R., Heym, K., Laetsch, T. W., Widener, M., Rheingold, S. R., Oesterheld, J., Hijiya, N., Sulis, M. L., Huynh, V., Place, A. E., Bittencourt, H., Hutchinson, R., Messinger, Y., Chang, B., … Whitlock, J. A. (2018). Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: A therapeutic advances in childhood leukemia & lymphoma study. Leukemia, 32(11), 2316–2325. https://doi.org/10.1038/s41375-018-0094-0
Google Scholar | Crossref | Medline Teachey, D. T., Lacey, S. F., Shaw, P. A., Melenhorst, J. J., Maude, S. L., Frey, N., Pequignot, E., Gonzalez, V. E., Chen, F., Finklestein, J., Barrett, D. M., Weiss, S. L., Fitzgerald, J. C., Berg, R. A., Aplenc, R., Callahan, C., Rheingold, S. R., Zheng, Z., Rose-John, S., … Grupp, S. A. (2016). Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor t-cell therapy for acute lymphoblastic leukemia. Cancer Discovery, 6(6), 664–679. https://doi.org/10.1158/2159-8290.cd-16-0040
Google Scholar | Crossref | Medline von Stackelberg, A., Locatelli, F., Zugmaier, G., Handgretinger, R., Trippett, T. M., Rizzari, C., Bader, P., O’Brien, M. M., Brethon, B., Bhojwani, D., Schlegel, P. G., Borkhardt, A., Rheingold, S. R., Cooper, T. M., Zwaan, C. M., Barnette, P., Messina, C., Michel, G., DuBois, SG., … Gore, L. (2016). Phase I/phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. Journal of Clinical Oncology, 34(36), 4381–4389. https://doi.org/10.1200/jco.2016.67.3301
Google Scholar | Crossref | Medline Wang, Z., Han, W. (2018). Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy. Biomarker Research, 6, https://doi.org/10.1186/s40364-018-0116-0
Google Scholar | Crossref Wilke, A. C., Gökbuget, N. (2017). Clinical applications and safety evaluation of the new CD19 specific T-cell engager antibody construct blinatumomab. Expert Opinion on Drug Safety, 16(10), 1191–1202. https://doi.org/10.1080/14740338.2017.1338270
Google Scholar | Crossref | Medline